Exact Mass: 403.26422340000005
Exact Mass Matches: 403.26422340000005
Found 409 metabolites which its exact mass value is equals to given mass value 403.26422340000005,
within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error
0.01 dalton.
3,4-Dihydroxy-tamoxifen
3,4-Dihydroxy-tamoxifen is a metabolite of tamoxifen. Tamoxifen is an antagonist of the estrogen receptor in breast tissue via its active metabolite, hydroxytamoxifen. In other tissues such as the endometrium, it behaves as an agonist, and thus may be characterized as a mixed agonist/antagonist. Tamoxifen is the usual endocrine therapy for hormone receptor-positive breast cancer in pre-menopausal women, and is also a standard in post-menopausal women although aromatase inhibitors are also frequently used in that setting. (Wikipedia)
N-Palmitoyl phenylalanine
N-palmitoyl phenylalanine belongs to the class of compounds known as N-acylamides. These are molecules characterized by a fatty acyl group linked to a primary amine by an amide bond. More specifically, it is a Palmitic acid amide of Phenylalanine. It is believed that there are more than 800 types of N-acylamides in the human body. N-acylamides fall into several categories: amino acid conjugates (e.g., those acyl amides conjugated with amino acids), neurotransmitter conjugates (e.g., those acylamides conjugated with neurotransmitters), ethanolamine conjugates (e.g., those acylamides conjugated to ethanolamine), and taurine conjugates (e.g., those acyamides conjugated to taurine). N-Palmitoyl phenylalanine is an amino acid conjugate. N-acylamides can be classified into 9 different categories depending on the size of their acyl-group: 1) short-chain N-acylamides; 2) medium-chain N-acylamides; 3) long-chain N-acylamides; and 4) very long-chain N-acylamides; 5) hydroxy N-acylamides; 6) branched chain N-acylamides; 7) unsaturated N-acylamides; 8) dicarboxylic N-acylamides and 9) miscellaneous N-acylamides. N-Palmitoyl phenylalanine is therefore classified as a long chain N-acylamide. N-acyl amides have a variety of signaling functions in physiology, including in cardiovascular activity, metabolic homeostasis, memory, cognition, pain, motor control and others (PMID: 15655504). N-acyl amides have also been shown to play a role in cell migration, inflammation and certain pathological conditions such as diabetes, cancer, neurodegenerative disease, and obesity (PMID: 23144998; PMID: 25136293; PMID: 28854168).N-acyl amides can be synthesized both endogenously and by gut microbiota (PMID: 28854168). N-acylamides can be biosynthesized via different routes, depending on the parent amine group. N-acyl ethanolamines (NAEs) are formed via the hydrolysis of an unusual phospholipid precursor, N-acyl-phosphatidylethanolamine (NAPE), by a specific phospholipase D. N-acyl amino acids are synthesized via a circulating peptidase M20 domain containing 1 (PM20D1), which can catalyze the bidirectional the condensation and hydrolysis of a variety of N-acyl amino acids. The degradation of N-acylamides is largely mediated by an enzyme called fatty acid amide hydrolase (FAAH), which catalyzes the hydrolysis of N-acylamides into fatty acids and the biogenic amines. Many N-acylamides are involved in lipid signaling system through interactions with transient receptor potential channels (TRP). TRP channel proteins interact with N-acyl amides such as N-arachidonoyl ethanolamide (Anandamide), N-arachidonoyl dopamine and others in an opportunistic fashion (PMID: 23178153). This signaling system has been shown to play a role in the physiological processes involved in inflammation (PMID: 25136293). Other N-acyl amides, including N-oleoyl-glutamine, have also been characterized as TRP channel antagonists (PMID: 29967167). N-acylamides have also been shown to have G-protein-coupled receptors (GPCRs) binding activity (PMID: 28854168). The study of N-acylamides is an active area of research and it is likely that many novel N-acylamides will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered for these molecules.
3,11-Dihydroxytetradecanoylcarnitine
C21H41NO6 (403.29337260000005)
3,11-Dihydroxytetradecanoylcarnitine is an acylcarnitine. More specifically, it is an 3,11-Dihydroxytetradecanoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 3,11-Dihydroxytetradecanoylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine 3,11-Dihydroxytetradecanoylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
3,7-Dihydroxytetradecanoylcarnitine
C21H41NO6 (403.29337260000005)
3,7-Dihydroxytetradecanoylcarnitine is an acylcarnitine. More specifically, it is an 3,7-Dihydroxytetradecanoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 3,7-Dihydroxytetradecanoylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine 3,7-Dihydroxytetradecanoylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
3,13-Dihydroxytetradecanoylcarnitine
C21H41NO6 (403.29337260000005)
3,13-Dihydroxytetradecanoylcarnitine is an acylcarnitine. More specifically, it is an 3,13-Dihydroxytetradecanoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 3,13-Dihydroxytetradecanoylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine 3,13-Dihydroxytetradecanoylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
3,8-Dihydroxytetradecanoylcarnitine
C21H41NO6 (403.29337260000005)
3,8-Dihydroxytetradecanoylcarnitine is an acylcarnitine. More specifically, it is an 3,8-Dihydroxytetradecanoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 3,8-Dihydroxytetradecanoylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine 3,8-Dihydroxytetradecanoylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
3,4-Dihydroxytetradecanoylcarnitine
C21H41NO6 (403.29337260000005)
3,4-Dihydroxytetradecanoylcarnitine is an acylcarnitine. More specifically, it is an 3,4-Dihydroxytetradecanoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 3,4-Dihydroxytetradecanoylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine 3,4-Dihydroxytetradecanoylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
3,5-Dihydroxytetradecanoylcarnitine
C21H41NO6 (403.29337260000005)
3,5-Dihydroxytetradecanoylcarnitine is an acylcarnitine. More specifically, it is an 3,5-Dihydroxytetradecanoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 3,5-Dihydroxytetradecanoylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine 3,5-Dihydroxytetradecanoylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
3,10-Dihydroxytetradecanoylcarnitine
C21H41NO6 (403.29337260000005)
3,10-Dihydroxytetradecanoylcarnitine is an acylcarnitine. More specifically, it is an 3,10-Dihydroxytetradecanoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 3,10-Dihydroxytetradecanoylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine 3,10-Dihydroxytetradecanoylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
3,12-Dihydroxytetradecanoylcarnitine
C21H41NO6 (403.29337260000005)
3,12-Dihydroxytetradecanoylcarnitine is an acylcarnitine. More specifically, it is an 3,12-Dihydroxytetradecanoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 3,12-Dihydroxytetradecanoylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine 3,12-Dihydroxytetradecanoylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
3,6-Dihydroxytetradecanoylcarnitine
C21H41NO6 (403.29337260000005)
3,6-Dihydroxytetradecanoylcarnitine is an acylcarnitine. More specifically, it is an 3,6-Dihydroxytetradecanoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 3,6-Dihydroxytetradecanoylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine 3,6-Dihydroxytetradecanoylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
3,9-Dihydroxytetradecanoylcarnitine
C21H41NO6 (403.29337260000005)
3,9-Dihydroxytetradecanoylcarnitine is an acylcarnitine. More specifically, it is an 3,9-Dihydroxytetradecanoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 3,9-Dihydroxytetradecanoylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine 3,9-Dihydroxytetradecanoylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
N-Arachidonoyl Valine
N-arachidonoyl valine belongs to the class of compounds known as N-acylamides. These are molecules characterized by a fatty acyl group linked to a primary amine by an amide bond. More specifically, it is an Arachidonic acid amide of Valine. It is believed that there are more than 800 types of N-acylamides in the human body. N-acylamides fall into several categories: amino acid conjugates (e.g., those acyl amides conjugated with amino acids), neurotransmitter conjugates (e.g., those acylamides conjugated with neurotransmitters), ethanolamine conjugates (e.g., those acylamides conjugated to ethanolamine), and taurine conjugates (e.g., those acyamides conjugated to taurine). N-Arachidonoyl Valine is an amino acid conjugate. N-acylamides can be classified into 9 different categories depending on the size of their acyl-group: 1) short-chain N-acylamides; 2) medium-chain N-acylamides; 3) long-chain N-acylamides; and 4) very long-chain N-acylamides; 5) hydroxy N-acylamides; 6) branched chain N-acylamides; 7) unsaturated N-acylamides; 8) dicarboxylic N-acylamides and 9) miscellaneous N-acylamides. N-Arachidonoyl Valine is therefore classified as a long chain N-acylamide. N-acyl amides have a variety of signaling functions in physiology, including in cardiovascular activity, metabolic homeostasis, memory, cognition, pain, motor control and others (PMID: 15655504). N-acyl amides have also been shown to play a role in cell migration, inflammation and certain pathological conditions such as diabetes, cancer, neurodegenerative disease, and obesity (PMID: 23144998; PMID: 25136293; PMID: 28854168).N-acyl amides can be synthesized both endogenously and by gut microbiota (PMID: 28854168). N-acylamides can be biosynthesized via different routes, depending on the parent amine group. N-acyl ethanolamines (NAEs) are formed via the hydrolysis of an unusual phospholipid precursor, N-acyl-phosphatidylethanolamine (NAPE), by a specific phospholipase D. N-acyl amino acids are synthesized via a circulating peptidase M20 domain containing 1 (PM20D1), which can catalyze the bidirectional the condensation and hydrolysis of a variety of N-acyl amino acids. The degradation of N-acylamides is largely mediated by an enzyme called fatty acid amide hydrolase (FAAH), which catalyzes the hydrolysis of N-acylamides into fatty acids and the biogenic amines. Many N-acylamides are involved in lipid signaling system through interactions with transient receptor potential channels (TRP). TRP channel proteins interact with N-acyl amides such as N-arachidonoyl ethanolamide (Anandamide), N-arachidonoyl dopamine and others in an opportunistic fashion (PMID: 23178153). This signaling system has been shown to play a role in the physiological processes involved in inflammation (PMID: 25136293). Other N-acyl amides, including N-oleoyl-glutamine, have also been characterized as TRP channel antagonists (PMID: 29967167). N-acylamides have also been shown to have G-protein-coupled receptors (GPCRs) binding activity (PMID: 28854168). The study of N-acylamides is an active area of research and it is likely that many novel N-acylamides will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered for these molecules.
N-Eicosapentaenoyl Threonine
C24H37NO4 (403.27224420000005)
N-eicosapentaenoyl threonine belongs to the class of compounds known as N-acylamides. These are molecules characterized by a fatty acyl group linked to a primary amine by an amide bond. More specifically, it is an Eicosapentaenoic acid amide of Threonine. It is believed that there are more than 800 types of N-acylamides in the human body. N-acylamides fall into several categories: amino acid conjugates (e.g., those acyl amides conjugated with amino acids), neurotransmitter conjugates (e.g., those acylamides conjugated with neurotransmitters), ethanolamine conjugates (e.g., those acylamides conjugated to ethanolamine), and taurine conjugates (e.g., those acyamides conjugated to taurine). N-Eicosapentaenoyl Threonine is an amino acid conjugate. N-acylamides can be classified into 9 different categories depending on the size of their acyl-group: 1) short-chain N-acylamides; 2) medium-chain N-acylamides; 3) long-chain N-acylamides; and 4) very long-chain N-acylamides; 5) hydroxy N-acylamides; 6) branched chain N-acylamides; 7) unsaturated N-acylamides; 8) dicarboxylic N-acylamides and 9) miscellaneous N-acylamides. N-Eicosapentaenoyl Threonine is therefore classified as a long chain N-acylamide. N-acyl amides have a variety of signaling functions in physiology, including in cardiovascular activity, metabolic homeostasis, memory, cognition, pain, motor control and others (PMID: 15655504). N-acyl amides have also been shown to play a role in cell migration, inflammation and certain pathological conditions such as diabetes, cancer, neurodegenerative disease, and obesity (PMID: 23144998; PMID: 25136293; PMID: 28854168).N-acyl amides can be synthesized both endogenously and by gut microbiota (PMID: 28854168). N-acylamides can be biosynthesized via different routes, depending on the parent amine group. N-acyl ethanolamines (NAEs) are formed via the hydrolysis of an unusual phospholipid precursor, N-acyl-phosphatidylethanolamine (NAPE), by a specific phospholipase D. N-acyl amino acids are synthesized via a circulating peptidase M20 domain containing 1 (PM20D1), which can catalyze the bidirectional the condensation and hydrolysis of a variety of N-acyl amino acids. The degradation of N-acylamides is largely mediated by an enzyme called fatty acid amide hydrolase (FAAH), which catalyzes the hydrolysis of N-acylamides into fatty acids and the biogenic amines. Many N-acylamides are involved in lipid signaling system through interactions with transient receptor potential channels (TRP). TRP channel proteins interact with N-acyl amides such as N-arachidonoyl ethanolamide (Anandamide), N-arachidonoyl dopamine and others in an opportunistic fashion (PMID: 23178153). This signaling system has been shown to play a role in the physiological processes involved in inflammation (PMID: 25136293). Other N-acyl amides, including N-oleoyl-glutamine, have also been characterized as TRP channel antagonists (PMID: 29967167). N-acylamides have also been shown to have G-protein-coupled receptors (GPCRs) binding activity (PMID: 28854168). The study of N-acylamides is an active area of research and it is likely that many novel N-acylamides will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered for these molecules.
metergoline
Spergualin
C17H37N7O4 (403.29068820000003)
2-amino-3,4,14-trihydroxy-2-hydroxymethyl-6-eicosenoic acid
C21H41NO6 (403.29337260000005)
4-phenyl-9-(3-phenyl-acryloyl)-1,5,9-triaza-cyclotridec-10-en-2-one|Neoperiphyllin|Neoperiphylline
macrodumine C|methyl (4S,6R,6?S,10aR,11S)-6?-ethyl-2,3,4,5,5?,6,6?,7,8,10-decahydro-6,6?-dihydroxy-2-methyl-1H,4?H-spiro[4,10a-methanopentaleno[1,6-cd]azonine-11,3?-pyran]-9-carboxylate
C23H33NO5 (403.23586080000007)
macrodumine A|methyl (4S,6?S,8aR,9R,10aR,11S)-6?-ethyl-2,3,4,5,5?,6,6?,7,8,8a,9,10-dodecahydro-6?-hydroxy-2-methyl-7-oxo-1H,4?H-spiro[4,10a-methanopentaleno[1,6-cd]azonine-11,3?-pyran]-9-carboxylate
C23H33NO5 (403.23586080000007)
(2R,3R,4bR,6aS,12bS,12cS,14aS)-4b-deoxypenijanthine A
C27H33NO2 (403.25111580000004)
hemsleyaconitine G|rel-(2R,3S,4aR,8S,11S)-13-ethyl-1,3,4,5,6,8,9,10,11,11b-decahydro-3,11-dimethoxy-8-(methoxymethyl)-2H-2,4a-methano-8,11a-(methanoiminomethano)dibenzo[a,c][7]annulen-15-one
C24H37NO4 (403.27224420000005)
Val Ser Ala Lys
Metergoline
An ergoline alkaloid that is the N-benzyloxycarbonyl derivative of lysergamine. A 5-HT2 antagonist. Also 5-HT1 antagonist and 5-HT1D ligand. Has moderate affinity for 5-HT6 and high affinity for 5-HT7. G - Genito urinary system and sex hormones > G02 - Other gynecologicals > G02C - Other gynecologicals > G02CB - Prolactine inhibitors D018377 - Neurotransmitter Agents > D018490 - Serotonin Agents > D012702 - Serotonin Antagonists D018377 - Neurotransmitter Agents > D015259 - Dopamine Agents > D018491 - Dopamine Agonists C78272 - Agent Affecting Nervous System > C66884 - Dopamine Agonist relative retention time with respect to 9-anthracene Carboxylic Acid is 0.923 relative retention time with respect to 9-anthracene Carboxylic Acid is 0.918 Metergoline is a serotonin (5-HT) receptor and dopamine receptors antagonist, with pKis of 8.64, 8.75 and 8.75 for 5-HT2A, 5-HT2B and 5-HT2C, respectively. Metergoline is a high-affinity ligand for the h5-HT7 receptor, with a Ki of 16 nM. Metergoline is also a reversible neural Na+ channels inhibitor. Metergoline is commonly used for the research of seasonal affective disorder, prolactin hormone regulation[1][2][3].
2-(14-methylpentadecanoylamino)-3-phenylpropanoic acid
C24H37NO4_(7E)-11-Hydroxy-3-isobutyl-12-methoxy-4,5,8-trimethyl-2,3,3a,4,6a,9,10,11,12,13-decahydrocyclodeca[d]isoindole-1,14-dione
C24H37NO4 (403.27224420000005)
2-(14-methylpentadecanoylamino)-3-phenylpropanoic acid [IIN-based on: CCMSLIB00000845077]
2-(14-methylpentadecanoylamino)-3-phenylpropanoic acid [IIN-based: Match]
Ala Ala Arg Ser
Ala Ala Ser Arg
Ala Gly Arg Thr
Ala Gly Thr Arg
Ala Lys Ser Val
Ala Lys Val Ser
Ala Arg Ala Ser
Ala Arg Gly Thr
Ala Arg Ser Ala
Ala Arg Thr Gly
Ala Ser Ala Arg
Ala Ser Lys Val
Ala Ser Arg Ala
Ala Ser Val Lys
Ala Thr Gly Arg
Ala Thr Arg Gly
Ala Val Lys Ser
Ala Val Ser Lys
Gly Ala Arg Thr
Gly Ala Thr Arg
Gly Ile Lys Ser
Gly Ile Ser Lys
Gly Lys Ile Ser
Gly Lys Leu Ser
Gly Lys Ser Ile
Gly Lys Ser Leu
Gly Lys Thr Val
Gly Lys Val Thr
Gly Leu Lys Ser
Gly Leu Ser Lys
Gly Arg Ala Thr
Gly Arg Thr Ala
Gly Ser Ile Lys
Gly Ser Lys Ile
Gly Ser Lys Leu
Gly Ser Leu Lys
Gly Thr Ala Arg
Gly Thr Lys Val
Gly Thr Arg Ala
Gly Thr Val Lys
Gly Val Lys Thr
Gly Val Thr Lys
Ile Gly Lys Ser
Ile Gly Ser Lys
Ile Lys Gly Ser
Ile Lys Ser Gly
Ile Ser Gly Lys
Ile Ser Lys Gly
Lys Ala Ser Val
Lys Ala Val Ser
Lys Gly Ile Ser
Lys Gly Leu Ser
Lys Gly Ser Ile
Lys Gly Ser Leu
Lys Gly Thr Val
Lys Gly Val Thr
Lys Ile Gly Ser
Lys Ile Ser Gly
Lys Leu Gly Ser
Lys Leu Ser Gly
Lys Ser Ala Val
Lys Ser Gly Ile
Lys Ser Gly Leu
Lys Ser Ile Gly
Lys Ser Leu Gly
Lys Ser Val Ala
Lys Thr Gly Val
Lys Thr Val Gly
Lys Val Ala Ser
Lys Val Gly Thr
Lys Val Ser Ala
Lys Val Thr Gly
Leu Gly Lys Ser
Leu Gly Ser Lys
Leu Lys Gly Ser
Leu Lys Ser Gly
Leu Ser Gly Lys
Leu Ser Lys Gly
Arg Ala Ala Ser
Arg Ala Gly Thr
Arg Ala Ser Ala
Arg Ala Thr Gly
Arg Gly Ala Thr
Arg Gly Thr Ala
Arg Ser Ala Ala
Arg Thr Ala Gly
Arg Thr Gly Ala
Ser Ala Ala Arg
Ser Ala Lys Val
Ser Ala Arg Ala
Ser Ala Val Lys
Ser Gly Ile Lys
Ser Gly Lys Ile
Ser Gly Lys Leu
Ser Gly Leu Lys
Ser Ile Gly Lys
Ser Ile Lys Gly
Ser Lys Ala Val
Ser Lys Gly Ile
Ser Lys Gly Leu
Ser Lys Ile Gly
Ser Lys Leu Gly
Ser Lys Val Ala
Ser Leu Gly Lys
Ser Leu Lys Gly
Ser Arg Ala Ala
Ser Val Ala Lys
Ser Val Lys Ala
Thr Ala Gly Arg
Thr Ala Arg Gly
Thr Gly Ala Arg
Thr Gly Lys Val
Thr Gly Arg Ala
Thr Gly Val Lys
Thr Lys Gly Val
Thr Lys Val Gly
Thr Arg Ala Gly
Thr Arg Gly Ala
Thr Val Gly Lys
Thr Val Lys Gly
Val Ala Lys Ser
Val Ala Ser Lys
Val Gly Lys Thr
Val Gly Thr Lys
Val Lys Ala Ser
Val Lys Gly Thr
Val Lys Ser Ala
Val Lys Thr Gly
Val Ser Lys Ala
Val Thr Gly Lys
Val Thr Lys Gly
methyl amide
C23H33NO5 (403.23586080000007)
ACETIC ACID (2S,3S)-3-DIBENZYLAMINO-2-HYDROXY-4-PHENYLBUTYL ESTER
ACETIC ACID (2R,3S)-3-DIBENZYLAMINO-2-HYDROXY-4-PHENYLBUTYL ESTER
bis(2-hydroxyethyl)methyloctylammonium toluene-p-sulphonate
C20H37NO5S (403.23923120000006)
benzyl 3-[3-[[(2-methylpropan-2-yl)oxycarbonylamino]methyl]azetidin-1-yl]piperidine-1-carboxylate
C22H33N3O4 (403.2470938000001)
Azepino[4,5-b]indole-5-carboxylic acid, 1,2,3,6-tetrahydro-1,1-dimethyl-8-[methyl(phenylmethyl)amino]-, ethyl ester
1H-Indole-1-carboxylic acid, 3-(1-cyano-1-methylethyl)-6-[methyl(phenylmethyl)amino]-, 1,1-dimethylethyl ester
(4-cyanophenyl) 4-(4-heptylcyclohexyl)benzoate
C27H33NO2 (403.25111580000004)
[5-[[[3-(dimethylamino)-2,2-dimethylpropyl]amino]methyl]-1-[(2-methylpropan-2-yl)oxycarbonyl]indol-2-yl]boronic acid
C21H34BN3O4 (403.26422340000005)
[5-[[4-(2-hydroxyethyl)piperazin-1-yl]methyl]-1-[(2-methylpropan-2-yl)oxycarbonyl]indol-2-yl]boronic acid
dicyclohexyl-[2-(2-methylphenyl)indol-1-yl]phosphane
2-[4-(Boc-amino)-1-piperidinyl]pyridine-5-boronic acid pinacol ester
C21H34BN3O4 (403.26422340000005)
2-[2-[4-[(2-cyanoethyl)methylamino]phenyl]vinyl]-1,3,3-trimethyl-3H-indolium acetate
TERT-BUTYL 4-(3-METHYL-5-(4,4,5,5-TETRAMETHYL-1,3,2-DIOXABOROLAN-2-YL)PYRIDIN-2-YL)PIPERAZINE-1-CARBOXYLATE
C21H34BN3O4 (403.26422340000005)
(+)-N-Acetyl 3,4,4a,5,6,10b-Hexahydro-2H-naphtho[1,2-β][1,4]oxazine-9-ol Triisopropylsilyl Ether
C23H37NO3Si (403.25425720000004)
tert-Butyl 4-(4-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-yl)piperazine-1-carboxylate
C21H34BN3O4 (403.26422340000005)
Amotriphene
C78274 - Agent Affecting Cardiovascular System > C47793 - Antiarrhythmic Agent C78274 - Agent Affecting Cardiovascular System > C29707 - Vasodilating Agent
N-((2-Methoxypyridin-4-yl)methyl)-1-(1-(naphthalen-1-yl)ethyl)piperidine-4-carboxamide
(R)-N-((2-Methoxypyridin-4-yl)methyl)-1-(1-(naphthalen-1-yl)ethyl)piperidine-4-carboxamide
Methyl 4-{[({[(2R,5S)-5-{[(2S)-2-(aminomethyl)pyrrolidin-1-YL]carbonyl}pyrrolidin-2-YL]methyl}amino)carbonyl]amino}benzoate
C20H29N5O4 (403.22194340000004)
3,7-Dihydroxytetradecanoylcarnitine
C21H41NO6 (403.29337260000005)
3,8-Dihydroxytetradecanoylcarnitine
C21H41NO6 (403.29337260000005)
3,4-Dihydroxytetradecanoylcarnitine
C21H41NO6 (403.29337260000005)
3,5-Dihydroxytetradecanoylcarnitine
C21H41NO6 (403.29337260000005)
3,6-Dihydroxytetradecanoylcarnitine
C21H41NO6 (403.29337260000005)
3,9-Dihydroxytetradecanoylcarnitine
C21H41NO6 (403.29337260000005)
3,11-Dihydroxytetradecanoylcarnitine
C21H41NO6 (403.29337260000005)
3,13-Dihydroxytetradecanoylcarnitine
C21H41NO6 (403.29337260000005)
3,10-Dihydroxytetradecanoylcarnitine
C21H41NO6 (403.29337260000005)
3,12-Dihydroxytetradecanoylcarnitine
C21H41NO6 (403.29337260000005)
N-oleoylethanolamine phosphate(2-)
C20H38NO5P-2 (403.24874680000005)
2-(3,5-dimethyl-1-pyrazolyl)-N-[[3-(4-fluorophenyl)-1-(4-methylphenyl)-4-pyrazolyl]methyl]ethanamine
N-[(2S,3S)-2-[(dimethylamino)methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]cyclopropanecarboxamide
C22H33N3O4 (403.2470938000001)
N-[(2S,3S)-2-[(dimethylamino)methyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]cyclopropanecarboxamide
C22H33N3O4 (403.2470938000001)
(2R,3S)-2-[[cyclopropylmethyl(methyl)amino]methyl]-9-(dimethylamino)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2,3,4,7-tetrahydro-1,5-benzoxazonin-6-one
(2R,3R)-2-[[cyclopropylmethyl(methyl)amino]methyl]-9-(dimethylamino)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2,3,4,7-tetrahydro-1,5-benzoxazonin-6-one
(2S,3S)-2-[[cyclopropylmethyl(methyl)amino]methyl]-9-(dimethylamino)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2,3,4,7-tetrahydro-1,5-benzoxazonin-6-one
N-[(5R,6R,9R)-5-methoxy-3,6,9-trimethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]cyclobutanecarboxamide
C22H33N3O4 (403.2470938000001)
N-[(5R,6R,9S)-5-methoxy-3,6,9-trimethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]cyclobutanecarboxamide
C22H33N3O4 (403.2470938000001)
2-[(3R,6aS,8S,10aS)-3-hydroxy-1-methyl-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-1-(4-phenyl-1-piperazinyl)ethanone
C22H33N3O4 (403.2470938000001)
(3aS,4R,9bR)-4-(hydroxymethyl)-5-methyl-8-(2-phenylethynyl)-N-propan-2-yl-3,3a,4,9b-tetrahydro-2H-pyrrolo[3,2-c]quinoline-1-carboxamide
[(8S,9R,10S)-9-[4-(1-cyclopentenyl)phenyl]-6-(pyridin-4-ylmethyl)-1,6-diazabicyclo[6.2.0]decan-10-yl]methanol
C26H33N3O (403.26234880000004)
N-[(2S,3R)-2-[(dimethylamino)methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]cyclopropanecarboxamide
C22H33N3O4 (403.2470938000001)
N-[(2R,3S)-2-[(dimethylamino)methyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]cyclopropanecarboxamide
C22H33N3O4 (403.2470938000001)
N-[(2S,3R)-2-[(dimethylamino)methyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]cyclopropanecarboxamide
C22H33N3O4 (403.2470938000001)
N-[(2R,3R)-2-[(dimethylamino)methyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]cyclopropanecarboxamide
C22H33N3O4 (403.2470938000001)
N-[(2R,3R)-2-[(dimethylamino)methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]cyclopropanecarboxamide
C22H33N3O4 (403.2470938000001)
(2R,3R)-2-[[cyclopropylmethyl(methyl)amino]methyl]-9-(dimethylamino)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2,3,4,7-tetrahydro-1,5-benzoxazonin-6-one
(2S,3S)-2-[[cyclopropylmethyl(methyl)amino]methyl]-9-(dimethylamino)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2,3,4,7-tetrahydro-1,5-benzoxazonin-6-one
N-[(5S,6R,9R)-5-methoxy-3,6,9-trimethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]cyclobutanecarboxamide
C22H33N3O4 (403.2470938000001)
N-[(5S,6S,9S)-5-methoxy-3,6,9-trimethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]cyclobutanecarboxamide
C22H33N3O4 (403.2470938000001)
N-[(5S,6S,9R)-5-methoxy-3,6,9-trimethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]cyclobutanecarboxamide
C22H33N3O4 (403.2470938000001)
N-[(5R,6S,9R)-5-methoxy-3,6,9-trimethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]cyclobutanecarboxamide
C22H33N3O4 (403.2470938000001)
N-[(5S,6R,9S)-5-methoxy-3,6,9-trimethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]cyclobutanecarboxamide
C22H33N3O4 (403.2470938000001)
(3aR,4S,9bS)-4-(hydroxymethyl)-5-methyl-8-(2-phenylethynyl)-N-propan-2-yl-3,3a,4,9b-tetrahydro-2H-pyrrolo[3,2-c]quinoline-1-carboxamide
[(8R,9S,10R)-9-[4-(1-cyclopentenyl)phenyl]-6-(pyridin-4-ylmethyl)-1,6-diazabicyclo[6.2.0]decan-10-yl]methanol
C26H33N3O (403.26234880000004)
4-[4-[(1S,5R)-3-[cyclobutyl(oxo)methyl]-3,6-diazabicyclo[3.1.1]heptan-7-yl]phenyl]-N,N-dimethylbenzamide
N-[4-(2,3,9,9-tetramethyl-7-oxo-6,6a,8,10-tetrahydro-5H-benzo[b][1,4]benzodiazepin-6-yl)phenyl]acetamide
(3R)-15-[(2R,3R,5R,6S)-3,5-dihydroxy-6-methyloxan-2-yl]oxy-3-hydroxypentadecanoate
(3R,14R)-14-[(2R,3R,5R,6S)-3,5-dihydroxy-6-methyloxan-2-yl]oxy-3-hydroxypentadecanoate
(4Z,7Z,10Z,13Z)-N-[(E)-1,3-dihydroxynon-4-en-2-yl]hexadeca-4,7,10,13-tetraenamide
2-(14-Methylpentadecanoylamino)-3-phenylpropanoic acid
4-(3-Acetyloxy-2-octanoyloxypropoxy)-2-(trimethylazaniumyl)butanoate
4-[2,3-Di(pentanoyloxy)propoxy]-2-(trimethylazaniumyl)butanoate
4-(2-Heptanoyloxy-3-propanoyloxypropoxy)-2-(trimethylazaniumyl)butanoate
4-(3-Butanoyloxy-2-hexanoyloxypropoxy)-2-(trimethylazaniumyl)butanoate
2-(2-Trimethylsilyloxyethoxy)-N-(2-(diethylamino)ethyl)-4-quinolinecarboxamide
7,12-dioxolithocholate
A cholanic acid anion that is the conjugate base of 7,12-dioxolithocholic acid, obtained by deprotonation of the carboxy group; major species at pH 7.3.
methyl 6-hydroxy-6-isopropyl-3'-methyl-3'-azaspiro[oxane-3,15'-tetracyclo[6.5.1.1¹,⁵.0¹¹,¹⁴]pentadecan]-8'(14')-ene-12'-carboxylate
C24H37NO4 (403.27224420000005)
1-(8-hydroxy-6-phenyl-1,5,9-triazacyclotrideca-8,12-dien-1-yl)-3-phenylprop-2-en-1-one
methyl (1'r,3r,5's,6s,7's)-6-ethyl-6,7'-dihydroxy-3'-methyl-3'-azaspiro[oxane-3,15'-tetracyclo[6.5.1.1¹,⁵.0¹¹,¹⁴]pentadecane]-8'(14'),11'-diene-12'-carboxylate
C23H33NO5 (403.23586080000007)
(1s,2s,4r,5s,7r,12s,16s)-14-ethyl-5,16-dimethoxy-12-(methoxymethyl)-14-azapentacyclo[10.3.3.1⁴,⁷.0¹,¹¹.0²,⁷]nonadec-10-en-19-one
C24H37NO4 (403.27224420000005)
(2s)-2-{[(2e,4e,6r)-1,12-dihydroxy-4,6-dimethyldodeca-2,4-dien-1-ylidene]amino}-3-(4-hydroxyphenyl)propanoic acid
C23H33NO5 (403.23586080000007)
(2s)-2-{[(2e,4e,6s)-1,12-dihydroxy-4,6-dimethyldodeca-2,4-dien-1-ylidene]amino}-3-(4-hydroxyphenyl)propanoic acid
C23H33NO5 (403.23586080000007)
(1's,3r,5'r,6s,11's,12's)-6-isopropyl-6-methoxy-3'-methyl-3'-azaspiro[oxane-3,15'-tetracyclo[6.5.1.1¹,⁵.0¹¹,¹⁴]pentadecan]-8'(14')-ene-12'-carboxylic acid
C24H37NO4 (403.27224420000005)
(2e)-1-[(6r,10e)-8-hydroxy-6-phenyl-1,5,9-triazacyclotrideca-8,10-dien-1-yl]-3-phenylprop-2-en-1-one
methyl 6-ethyl-6,7'-dihydroxy-3'-methyl-3'-azaspiro[oxane-3,15'-tetracyclo[6.5.1.1¹,⁵.0¹¹,¹⁴]pentadecane]-8'(14'),11'-diene-12'-carboxylate
C23H33NO5 (403.23586080000007)
11-ethyl-4,6-dimethoxy-13-(methoxymethyl)-11-azahexacyclo[7.7.2.1²,⁵.0¹,¹⁰.0³,⁸.0¹³,¹⁷]nonadec-7-en-16-ol
C24H37NO4 (403.27224420000005)
2,11-dihydroxy-5,7-dimethyl-7-azaspiro[hexacyclo[7.6.2.2¹⁰,¹³.0¹,⁸.0⁵,¹⁶.0¹⁰,¹⁵]nonadecane-12,2'-oxiran]-18-yl acetate
C23H33NO5 (403.23586080000007)
methyl 6-ethyl-6-hydroxy-3'-methyl-7'-oxo-3'-azaspiro[oxane-3,15'-tetracyclo[6.5.1.1¹,⁵.0¹¹,¹⁴]pentadecan]-8'(14')-ene-12'-carboxylate
C23H33NO5 (403.23586080000007)
(1'r,3r,5's,6r,11'r,12'r)-6-isopropyl-6-methoxy-3'-methyl-3'-azaspiro[oxane-3,15'-tetracyclo[6.5.1.1¹,⁵.0¹¹,¹⁴]pentadecan]-8'(14')-ene-12'-carboxylic acid
C24H37NO4 (403.27224420000005)
5-hydroxy-4-{hydroxy[6-hydroxy-1,3,6-trimethyl-2-(prop-1-en-1-yl)-2,4a,5,7,8,8a-hexahydronaphthalen-1-yl]methylidene}-2-(1-hydroxyethyl)-2h-pyrrol-3-one
C23H33NO5 (403.23586080000007)
methyl 6-ethyl-6-methoxy-3'-methyl-3'-azaspiro[oxane-3,15'-tetracyclo[6.5.1.1¹,⁵.0¹¹,¹⁴]pentadecan]-8'(14')-ene-12'-carboxylate
C24H37NO4 (403.27224420000005)
5-[(1s)-1-hydroxy-3-{[(2e,4s,6r)-1-hydroxy-4,6,8-trimethylnona-2,7-dien-1-ylidene]amino}-4-oxocyclohexa-2,5-dien-1-yl]pentanoic acid
C23H33NO5 (403.23586080000007)
(2s,4e)-4-{[(1s,2r,4as,6r,8ar)-6-hydroxy-1,3,6-trimethyl-2-[(1e)-prop-1-en-1-yl]-2,4a,5,7,8,8a-hexahydronaphthalen-1-yl](hydroxy)methylidene}-5-hydroxy-2-[(1r)-1-hydroxyethyl]-2h-pyrrol-3-one
C23H33NO5 (403.23586080000007)
methyl (1'r,3r,5's,6r,11'r,12'r)-6-hydroxy-6-isopropyl-3'-methyl-3'-azaspiro[oxane-3,15'-tetracyclo[6.5.1.1¹,⁵.0¹¹,¹⁴]pentadecan]-8'(14')-ene-12'-carboxylate
C24H37NO4 (403.27224420000005)
(2e)-1-[(6s,12z)-8-hydroxy-6-phenyl-1,5,9-triazacyclotrideca-8,12-dien-1-yl]-3-phenylprop-2-en-1-one
(2r,3r,4s,7r,8s,12r,15s)-4,7,8,16,16-pentamethyl-22-azahexacyclo[15.6.1.0²,¹⁵.0³,¹².0⁷,¹².0²¹,²⁴]tetracosa-1(23),17(24),18,20-tetraen-11-one
n-{1-[7-(acetyloxy)-9a,11a-dimethyl-tetradecahydro-1h-cyclopenta[a]phenanthren-1-yl]ethyl}ethanimidic acid
5-[(2z,6z)-10,11-dihydroxy-3,7,11-trimethyldodeca-2,6-dien-1-yl]-3h-isoindole-1,4,6-triol
C23H33NO5 (403.23586080000007)
methyl (1'r,3r,5's,6r,11'r,12'r)-6-ethyl-6-hydroxy-3'-methyl-7'-oxo-3'-azaspiro[oxane-3,15'-tetracyclo[6.5.1.1¹,⁵.0¹¹,¹⁴]pentadecan]-8'(14')-ene-12'-carboxylate
C23H33NO5 (403.23586080000007)
1,2,9-trimethyl-7-(2-methylprop-1-en-1-yl)-6-oxa-22-azahexacyclo[11.10.0.0²,¹⁰.0⁵,⁹.0¹⁵,²³.0¹⁶,²¹]tricosa-15(23),16,18,20-tetraene
(1s,2r,3s,4s,5r,6s,9r,10r,13s,16r,17r)-11-ethyl-4,6-dimethoxy-13-(methoxymethyl)-11-azahexacyclo[7.7.2.1²,⁵.0¹,¹⁰.0³,⁸.0¹³,¹⁷]nonadec-7-en-16-ol
C24H37NO4 (403.27224420000005)
methyl (1'r,3r,5's,6s,11's,12's)-6-ethyl-6-methoxy-3'-methyl-3'-azaspiro[oxane-3,15'-tetracyclo[6.5.1.1¹,⁵.0¹¹,¹⁴]pentadecan]-8'(14')-ene-12'-carboxylate
C24H37NO4 (403.27224420000005)
2-[(1,12-dihydroxy-4,6-dimethyldodeca-2,4-dien-1-ylidene)amino]-3-(4-hydroxyphenyl)propanoic acid
C23H33NO5 (403.23586080000007)
9-hydroxy-7-phenyl-1,6,10-triazatricyclo[11.9.0.0¹⁴,¹⁹]docosa-9,14,16,18,20-pentaen-22-one
methyl (1'r,3r,5's,6s,11'r,12'r)-6-ethyl-6-hydroxy-3'-methyl-7'-oxo-3'-azaspiro[oxane-3,15'-tetracyclo[6.5.1.1¹,⁵.0¹¹,¹⁴]pentadecan]-8'(14')-ene-12'-carboxylate
C23H33NO5 (403.23586080000007)
(2z)-1-[(6r,10e)-8-hydroxy-6-phenyl-1,5,9-triazacyclotrideca-8,10-dien-1-yl]-3-phenylprop-2-en-1-one
15-isopropyl-18,19-dimethyl-11-azahexacyclo[13.7.2.0¹,¹⁸.0²,¹⁴.0⁴,¹².0⁵,¹⁰]tetracosa-2(14),4(12),5,7,9-pentaen-22-ol
2-{[(2e,4e)-1,12-dihydroxy-4,6-dimethyldodeca-2,4-dien-1-ylidene]amino}-3-(4-hydroxyphenyl)propanoic acid
C23H33NO5 (403.23586080000007)
5-{1-hydroxy-3-[(1-hydroxy-4,6,8-trimethylnona-2,7-dien-1-ylidene)amino]-4-oxocyclohexa-2,5-dien-1-yl}pentanoic acid
C23H33NO5 (403.23586080000007)
(7r,13r)-9-hydroxy-7-phenyl-1,6,10-triazatricyclo[11.9.0.0¹⁴,¹⁹]docosa-9,14,16,18,20-pentaen-22-one
methyl (1r,3r,4r,10r,14r,15r,17r,18s,19r)-17,19-dihydroxy-18-(hydroxymethyl)-14-methyl-12-azahexacyclo[10.6.1.1¹,⁴.0¹⁰,¹⁸.0¹⁵,¹⁹.0⁷,²⁰]icos-7(20)-ene-3-carboxylate
C23H33NO5 (403.23586080000007)
n-[(1s)-1-[(1r,3as,3br,5as,7s,9as,9bs,11as)-7-(acetyloxy)-9a,11a-dimethyl-tetradecahydro-1h-cyclopenta[a]phenanthren-1-yl]ethyl]ethanimidic acid
methyl (1's,3s,5'r,6s,11'r,12's)-6-ethyl-6-hydroxy-3'-methyl-7'-oxo-3'-azaspiro[oxane-3,15'-tetracyclo[6.5.1.1¹,⁵.0¹¹,¹⁴]pentadecan]-8'(14')-ene-12'-carboxylate
C23H33NO5 (403.23586080000007)
(1s,2s,5s,7r,9s,10r,13s)-1,2,9-trimethyl-7-(2-methylprop-1-en-1-yl)-6-oxa-22-azahexacyclo[11.10.0.0²,¹⁰.0⁵,⁹.0¹⁵,²³.0¹⁶,²¹]tricosa-15(23),16,18,20-tetraene
(1s,15r,18s,19r,22s)-15-isopropyl-18,19-dimethyl-11-azahexacyclo[13.7.2.0¹,¹⁸.0²,¹⁴.0⁴,¹².0⁵,¹⁰]tetracosa-2(14),4(12),5,7,9-pentaen-22-ol
methyl (1's,3r,5'r,6r,11'r,12'r)-6-hydroxy-6-isopropyl-3'-methyl-3'-azaspiro[oxane-3,15'-tetracyclo[6.5.1.1¹,⁵.0¹¹,¹⁴]pentadecan]-8'(14')-ene-12'-carboxylate
C24H37NO4 (403.27224420000005)
(2e)-1-[(6s,10z)-8-hydroxy-6-phenyl-1,5,9-triazacyclotrideca-8,10-dien-1-yl]-3-phenylprop-2-en-1-one
methyl (1's,3s,5'r,6r,11'r,12'r)-6-hydroxy-6-isopropyl-3'-methyl-3'-azaspiro[oxane-3,15'-tetracyclo[6.5.1.1¹,⁵.0¹¹,¹⁴]pentadecan]-8'(14')-ene-12'-carboxylate
C24H37NO4 (403.27224420000005)
4,7,8,16,16-pentamethyl-22-azahexacyclo[15.6.1.0²,¹⁵.0³,¹².0⁷,¹².0²¹,²⁴]tetracosa-1(23),17(24),18,20-tetraen-11-one
4,4a-dimethyl-13b-(4-methylpent-3-en-1-yl)-1h,2h,3h,4h,5h,6h,7h,8h,13h-naphtho[2,1-b]carbazol-1-ol
(1s,4r,4as,13br)-4,4a-dimethyl-13b-(4-methylpent-3-en-1-yl)-1h,2h,3h,4h,5h,6h,7h,8h,13h-naphtho[2,1-b]carbazol-1-ol
methyl (1'r,3r,5's,6s,11'r,12'r)-6-ethyl-6-methoxy-3'-methyl-3'-azaspiro[oxane-3,15'-tetracyclo[6.5.1.1¹,⁵.0¹¹,¹⁴]pentadecan]-8'(14')-ene-12'-carboxylate
C24H37NO4 (403.27224420000005)
5-(10,11-dihydroxy-3,7,11-trimethyldodeca-2,6-dien-1-yl)-3h-isoindole-1,4,6-triol
C23H33NO5 (403.23586080000007)
(1r,2s,5s,8r,9r,10s,11s,12s,13r,15r,16r,18s)-2,11-dihydroxy-5,7-dimethyl-7-azaspiro[hexacyclo[7.6.2.2¹⁰,¹³.0¹,⁸.0⁵,¹⁶.0¹⁰,¹⁵]nonadecane-12,2'-oxiran]-18-yl acetate
C23H33NO5 (403.23586080000007)
2-amino-n-[4-amino-3-({3-amino-6-[(ethylamino)methyl]oxan-2-yl}oxy)-2-hydroxy-6-methoxycyclohexyl]-n-methylacetamide
C18H37N5O5 (403.27945520000003)
(7s,13r)-9-hydroxy-7-phenyl-1,6,10-triazatricyclo[11.9.0.0¹⁴,¹⁹]docosa-9,14,16,18,20-pentaen-22-one
methyl (1r,3r,4r,10s,14s,15r,17r,18s,19r)-17,19-dihydroxy-18-(hydroxymethyl)-14-methyl-12-azahexacyclo[10.6.1.1¹,⁴.0¹⁰,¹⁸.0¹⁵,¹⁹.0⁷,²⁰]icos-7(20)-ene-3-carboxylate
C23H33NO5 (403.23586080000007)
6-isopropyl-6-methoxy-3'-methyl-3'-azaspiro[oxane-3,15'-tetracyclo[6.5.1.1¹,⁵.0¹¹,¹⁴]pentadecan]-8'(14')-ene-12'-carboxylic acid
C24H37NO4 (403.27224420000005)
(1r,2s,5s,8r,9r,11s,12s,13r,15r,16r,18s)-2,11-dihydroxy-5,7-dimethyl-7-azaspiro[hexacyclo[7.6.2.2¹⁰,¹³.0¹,⁸.0⁵,¹⁶.0¹⁰,¹⁵]nonadecane-12,2'-oxiran]-18-yl acetate
C23H33NO5 (403.23586080000007)
14-ethyl-5,16-dimethoxy-12-(methoxymethyl)-14-azapentacyclo[10.3.3.1⁴,⁷.0¹,¹¹.0²,⁷]nonadec-10-en-19-one
C24H37NO4 (403.27224420000005)
1-[(1s,2r,3r,4s,5s,6s,8r,9s,10r,13r,16s,17r)-11-ethyl-8,16-dihydroxy-6-methoxy-13-methyl-11-azahexacyclo[7.7.2.1²,⁵.0¹,¹⁰.0³,⁸.0¹³,¹⁷]nonadecan-4-yl]ethanone
C24H37NO4 (403.27224420000005)
(5r)-3-methyl-5-[(1s,2r,3s,4s,6r,11s)-3-methyl-11-[(2s,4s)-4-methyl-5-oxooxolan-2-yl]-5-oxa-10-azatricyclo[8.4.0.0²,⁶]tetradecan-4-yl]-5h-furan-2-one
C23H33NO5 (403.23586080000007)
methyl 3-[(3s,3ar,5ar,8ar,11br,11cs)-1-formyl-5a-(hydroxymethyl)-3-methyl-6-oxo-2h,3h,3ah,4h,5h,7h,8h,8ah,9h,10h,11ch-azuleno[5,4-g]indol-11b-yl]propanoate
C23H33NO5 (403.23586080000007)
1-(8-hydroxy-6-phenyl-1,5,9-triazacyclotrideca-8,10-dien-1-yl)-3-phenylprop-2-en-1-one
methyl 3-[1-formyl-5a-(hydroxymethyl)-3-methyl-6-oxo-2h,3h,3ah,4h,5h,7h,8h,8ah,9h,10h,11ch-azuleno[5,4-g]indol-11b-yl]propanoate
C23H33NO5 (403.23586080000007)